MiSaver® Stem Cell Treatment for Heart Attack (Acute Myocardial Infarction)

Honya Medical Inc11 enrolled

Overview

The objective of the present study is to establish the safety and efficacy of MiSaver® Stem Cell Treatment After a Heart Attack (Acute Myocardial Infarction)

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Myocardial Infarction

Interventions

MiSaver®BIOLOGICAL

Intravenous administration of MiSaver® Stem Cell via peripheral vein access.

Eligibility

Sex: ALLMin age: 20 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients aged 20\~80 * Acute Myocardial Infarction 1 to 10 days * Cardiac enzyme CK-MB or Troponin \> 2X of high-end normal value * ST-elevation on EKG (STEMI) * Presence of regional wall motion abnormality * Left ventricular ejection fraction (LVEF) of ≤40% * Hemodynamically stable past 24 hour * Participants with adequate pulmonary function * Peripheral artery oxygen saturation ≥97% * Karnofsky performance status scores of ≥60. Exclusion Criteria: * Age \<20 or \>80 * Pregnant or breast feeding * Positive adventitious infections (such as HIV, hepatitis ) * Revascularization via coronary artery bypass surgery is required * Coronary revascularization procedures is anticipated during the 6-month study period * Severe aortic or mitral valve narrowing * Evidence of life-threatening arrhythmia on baseline electrocardiogram (ECG) * Short of breath unable to receive PCI examination or treatment * Malignant tumor * Hematopoietic dysplasia * Severe organ disease * With less than 1 year of life expectancy * Chronic kidney disease with CCr\<20ml/min * Kidney disease on renal dialysis

Locations (2)

Chung Shan Medical University Hospital

Taichung, Taichung City, Taiwan

HONYA Medical Inc

Tainan, Taiwan

Outcomes

Primary Outcomes

Incidence of Treatment Emergent Adverse Events

Number of Adverse Events

Time frame: 12 months

Secondary Outcomes

Left ventricle stroke volume

Echocardiogram assessment on left ventricle stroke volume (volume of blood pumped from the left ventricle per beat (ml).

Time frame: 12 months

End diastolic volume

Echocardiogram assessment on volume of blood in the left ventricle at the end of diastolic filling (cc)

Time frame: 12 months

Left ventricular ejection fraction (LVEF)

Calculated by dividing the volume of blood pumped from the left ventricle per beat (stroke volume) by the volume of blood collected in the left ventricle at the end of diastolic filling (end-diastolic volume).

Time frame: 12 months

Participants Functional Activity by NYHA Classification

The New York Heart Association (NYHA) Functional Classification is a useful tool for classifying the extent of functional limitations in patients with heart conditions. The system categorizes patients into one of four categories based on the level of limitation they experience during physical activity, with symptoms ranging from mild shortness of breath or angina to more severe breathing difficulties. The NYHA classification focuses specifically on limitations related to physical activity and provides a straightforward approach to assessing a patient's condition. By using this system, healthcare providers can quickly and easily determine the level of functional limitation in their patients and tailor treatment plans accordingly.

Time frame: 12 months

Participants Functional Activity by CCS Classification

The Canadian Cardiovascular Society grading of angina pectoris, also known as the CCS Functional Classification, is a widely used clinical tool that classifies the severity of exertional angina. It allows doctors to assess the degree of angina severity in patients, and subsequently develop a tailored treatment plan. Although there are no definitive therapy guidelines specific to each class, healthcare providers can use the CCS grading system as a framework to guide treatment planning based on the severity of angina and other individual factors such as age and the risk of major cardiac complications. By utilizing the CCS grading system, healthcare providers can ensure that patients receive personalized treatment that addresses their unique needs and circumstances.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.